FTC Cracks Down on False Advertising in Dietary Supplements

by Morgan Lewis

Supplements making claims regarding diabetes, genetically customized nutritional benefits, and weight loss are slammed for false advertising.

Recent Federal Trade Commission (FTC) enforcement activities—including a ruling by the U.S. District Court for the Northern District of California against the marketer of a diabetes treatment and settlements with marketers of genetically customized dietary supplements and weight-loss food and dietary supplement products—reflect a significant push by the FTC to crack down on unsubstantiated claims for dietary supplements and other health products. This recent activity serves as a reminder of the following for marketers of dietary supplements:

  • They must have adequate substantiation in their files before making claims.
  • “Adequate substantiation” for health claims likely means two double-blind, placebo-controlled, human studies with statistically significant results.
  • Review and approval of promotional and labeling materials should be a formal, standardized process.
  • Employees at all levels and agents engaged by the company should be aware of and trained on the importance of these principles.

Wellness Support Network Inc.

On February 19, the Northern District of California ruled that Wellness Support Network Inc. must pay $2.2 million in restitution and issued a 20-year injunction forbidding the company’s owners from falsely advertising diabetes treatments. This ruling was the result of FTC Act violations stemming from online sales of “diabetes pack” and “insulin resistance pack” supplements.[1]

The FTC filed suit in 2010 against Wellness Support Network based on false and misleading advertising claims about their products’ ability to lower blood sugar levels and reduce dependency on insulin and other medications that treat diabetes. The court rejected Wellness’s assertion that First Amendment principles of commercial free speech were a defense, stating that relevant case law does not stand for the principle that “a manufacturer or seller of dietary supplements—or for that matter, any product—has a First Amendment right to make claims that are false or deceptive.”

Operation Failed Resolution

In early January, the FTC announced settlements with marketers of food, dietary supplements, and cosmetic products in “Operation Failed Resolution,” an initiative aimed at stopping deceptive weight-loss advertising claims.[2] As part of “Operation Failed Resolution,” the FTC reached four settlements with marketers of deceptive weight-loss products: Sensa Products, L’Occitane Inc., HCG Diet Direct, and LeanSpa. All four companies are barred from making weight-loss claims about dietary supplements, foods, or drugs unless they have two adequate and well-controlled human clinical studies supporting the claims.

As part of “Operation Failed Resolution,” the FTC released an updated guidance document for spotting false weight-loss claims in advertising titled “Gut Check: A Reference Guide for Media on Spotting False Weight-Loss Claims.”[3] The FTC also sent a letter to publishers and broadcasters to help them use the guidance to screen out deceptive diet ads and also encouraged them to train their staff on claims discussed in the “Gut Check” guidance.[4]

Genetically Customized Nutritional Supplements

Separately, but on the same day as the announcements regarding “Operation Failed Resolution,” the FTC announced its proposed settlement with GeneLink, Inc. and foru International Corporation, marketers of genetically customized nutritional supplements.[5] The companies’ marketing materials included claims that the products could compensate for an individual’s genetic disadvantages (as determined by an assessment of DNA obtained from a swab of a consumer’s cheek), including serious conditions like diabetes and heart disease. Additionally, claims for a skin serum product said that the effectiveness of the product was scientifically proven, citing a “double blind, randomized and controlled study” that apparently was based on Internet research.

Under the proposed settlements with the FTC, GeneLink and foru are prohibited from claiming that a drug, food, or cosmetic will treat, prevent, or reduce the risk of any disease by modulating the effect of genes or will have any particular effect based on a person’s customized genetic assessment unless the claim is true and supported by at least two adequate and well-controlled human clinical studies.


These recent developments confirm the FTC’s continuing and potentially increasing interest in taking enforcement action in the context of unsupported dietary supplement marketing claims. Manufacturers and marketers of dietary supplements, especially those that make weight-loss claims or that target special populations with their products, must be vigilant in ensuring that their claims are supported with credible scientific research and in promoting their products through reputable media outlets.

Although there is no express statutory requirement for two “adequate and well-controlled”[6] human clinical studies, the FTC and courts continue to signal that marketers will be held to this standard in the context of health claims, requiring rigorous clinical studies that support truthful statements about the results of the study in relation to the average consumer.

Thus, with few exceptions, health claims made for dietary supplements are deemed to require double-blind, placebo-controlled human subject studies. Moreover, the recent actions discussed above reinforce that the FTC requires a level of substantiation that is reasonably tailored to the specific claims being made.

The FTC’s “Gut Check” guidance and its January 7, 2014 letter to publishers and broadcasters also reflect a push to increase awareness about claims substantiation for dietary supplement advertisements at all levels of product promotion and marketing. This broad-brush approach supports the conclusion that a documented process for the review and approval of promotional and labeling claims should be implemented by manufacturers at all levels of production, even where the claims are made by advertisers they hire. Further, the wide-reaching nature of the FTC’s awareness campaign will likely trigger additional scrutiny from third parties, including consumers and competitors.

The FTC’s effort to target such a broad audience with its recommendations also may signal that it is looking closely at the role of publishers and broadcasters in propagating claims that are made on behalf of dietary supplement marketers, which stands to further complicate advertising strategies for manufacturers of dietary supplements.

[1]. FTC v. Wellness Support Network, No. 3:10-cv-4879 CJS (N.D. Cal. Feb. 19, 2014); Andrew Scurria, FTC Bags $2M False Ad Win Against Diabetes Supplement Co., Law360 (Feb. 20, 2014), here.

[2]. Press Release, FTC, Sensa and Three Other Marketers of Fad Weight-Loss Products Settle FTC Charges in Crackdown on Deceptive Advertising (Jan. 7, 2014), available here.

[3]. Press Release, FTC, FTC Has Updated Guidance for Media Outlets on Spotting False Weight-Loss Claims in Advertising, (Jan. 7, 2014), available here; Bureau of Consumer Prot. Bus. Ctr., Gut Check: A Reference Guide for Media on Spotting False Weight Loss Claims, here (last visited Feb. 26, 2014).

[4]. Letter from Jessica Rich, Dir., Bureau of Consumer Prot., FTC, to unspecified publishers and broadcasters (Jan. 7, 2013), available here.

[5]. Press Release, FTC, Companies Pitching Genetically Customized Nutritional Supplements Will Drop Misleading Disease Claims (Jan. 7, 2014), available here

[6]. “Adequate and well-controlled” human clinical studies are defined to mean randomized human subject studies that (1) utilize valid endpoints generally recognized by experts in the relevant disease field; (2) are conducted by persons qualified by training and experience to conduct this type of study; (3) yield statistically significant results between groups; and (4) are conducted by persons qualified by training and experience.


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Morgan Lewis | Attorney Advertising

Written by:

Morgan Lewis

Morgan Lewis on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.